Value of molecular monitoring for minimal residual disease preceding autologous SCT following diagnosis of B cell acute lymphoblastic leukemia in patients treated with the MRC UKALL12 protocol.

Value of molecular monitoring for minimal residual disease preceding autologous SCT following diagnosis of B cell acute lymphoblastic leukemia in patients treated with the MRC UKALL12 protocol.

Détails bibliographiques
Auteurs principaux: Foroni, L, Mitchell, W, Rai, L, Casanova, A, Patel, B, Richards, S, Fielding, A, Goldstone, A
Format: Conference item
Publié: 2005

Documents similaires